a Delaware corporation) 5,600,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 4th, 2022 • Tarsus Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Tarsus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”), Jefferies LLC (“Jefferies”) and each of the other underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA and Jefferies are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 840,000 additional shares of Common Stock. The aforesaid 5,600,000 shares of Common Stock (the “Initial Securit
